Fatema Z Chowdhury1, Zhengyu Ouyang1, Maria Buzon1, Bruce D Walker1,2, Mathias Lichterfeld1,3, Xu G Yu1,3. 1. Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, Massachusetts. 2. Howard Hughes Medical Institute, Chevy Chase, Maryland. 3. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: Elite controllers, defined as persons maintaining undetectable levels of HIV-1 replication in the absence of antiretroviral therapy, represent living evidence that sustained, natural control of HIV-1 is possible, at least in relatively rare instances. Understanding the complex immunologic and virologic characteristics of these specific patients holds promise for inducing drug-free control of HIV-1 in broader populations of HIV-1 infected patients. DESIGN: We used an unbiased transcriptional profiling approach to characterize CD8+ T cells, the strongest correlate of HIV-1 immune control identified thus far, in a large cohort of elite controllers (n = 51); highly active antiretrovial therapy (HAART)-treated patients (n = 32) and HIV-1 negative (n = 10) served as reference cohorts. METHODS: We isolated mRNA from total CD8+ T cells isolated from peripheral blood mononuclear cell (PBMC) of each individual followed by microarray analysis of the transcriptional signatures. RESULTS: We observed profound transcriptional differences [590 transcripts, false discovery rate (FDR)-adjusted P < 0.05] between elite controller and HAART-treated patients. Interestingly, metabolic and signalling pathways governed by mammalian target of rapamycin (mTOR) and eIF2, known for their key roles in regulating cellular growth, proliferation and metabolism, were among the top functions enriched in the differentially expressed genes, suggesting a therapeutically actionable target as a distinguishing feature of spontaneous HIV-1 immune control. A subsequent bootstrapping approach distinguished five different subgroups of elite controller, each characterized by distinct transcriptional signatures. However, despite this marked heterogeneity, differential regulation of mTOR and eIF2 signalling remained the dominant functional pathway in three of these elite controller subgroups. CONCLUSION: These studies suggest that mTOR and eIF2 signalling may play a remarkably universal role for regulating CD8 T-cell function from elite controllers.
OBJECTIVE: Elite controllers, defined as persons maintaining undetectable levels of HIV-1 replication in the absence of antiretroviral therapy, represent living evidence that sustained, natural control of HIV-1 is possible, at least in relatively rare instances. Understanding the complex immunologic and virologic characteristics of these specific patients holds promise for inducing drug-free control of HIV-1 in broader populations of HIV-1 infectedpatients. DESIGN: We used an unbiased transcriptional profiling approach to characterize CD8+ T cells, the strongest correlate of HIV-1 immune control identified thus far, in a large cohort of elite controllers (n = 51); highly active antiretrovial therapy (HAART)-treated patients (n = 32) and HIV-1 negative (n = 10) served as reference cohorts. METHODS: We isolated mRNA from total CD8+ T cells isolated from peripheral blood mononuclear cell (PBMC) of each individual followed by microarray analysis of the transcriptional signatures. RESULTS: We observed profound transcriptional differences [590 transcripts, false discovery rate (FDR)-adjusted P < 0.05] between elite controller and HAART-treated patients. Interestingly, metabolic and signalling pathways governed by mammalian target of rapamycin (mTOR) and eIF2, known for their key roles in regulating cellular growth, proliferation and metabolism, were among the top functions enriched in the differentially expressed genes, suggesting a therapeutically actionable target as a distinguishing feature of spontaneous HIV-1 immune control. A subsequent bootstrapping approach distinguished five different subgroups of elite controller, each characterized by distinct transcriptional signatures. However, despite this marked heterogeneity, differential regulation of mTOR and eIF2 signalling remained the dominant functional pathway in three of these elite controller subgroups. CONCLUSION: These studies suggest that mTOR and eIF2 signalling may play a remarkably universal role for regulating CD8 T-cell function from elite controllers.
Authors: Yoshiaki Nishimura; Rajeev Gautam; Tae-Wook Chun; Reza Sadjadpour; Kathryn E Foulds; Masashi Shingai; Florian Klein; Anna Gazumyan; Jovana Golijanin; Mitzi Donaldson; Olivia K Donau; Ronald J Plishka; Alicia Buckler-White; Michael S Seaman; Jeffrey D Lifson; Richard A Koup; Anthony S Fauci; Michel C Nussenzweig; Malcolm A Martin Journal: Nature Date: 2017-03-13 Impact factor: 49.962
Authors: Gaurav D Gaiha; Kevin J McKim; Matthew Woods; Thomas Pertel; Janine Rohrbach; Natasha Barteneva; Christopher R Chin; Dongfang Liu; Damien Z Soghoian; Kevin Cesa; Shannon Wilton; Michael T Waring; Adam Chicoine; Travis Doering; E John Wherry; Daniel E Kaufmann; Mathias Lichterfeld; Abraham L Brass; Bruce D Walker Journal: Immunity Date: 2014-12-08 Impact factor: 31.745
Authors: Emily K Cartwright; Lori Spicer; S Abigail Smith; David Lee; Randy Fast; Sara Paganini; Benton O Lawson; Melon Nega; Kirk Easley; Joern E Schmitz; Steven E Bosinger; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Jacob D Estes; Jeffrey D Lifson; Cynthia A Derdeyn; Guido Silvestri Journal: Immunity Date: 2016-09-20 Impact factor: 31.745
Authors: Michael Quigley; Florencia Pereyra; Björn Nilsson; Filippos Porichis; Catia Fonseca; Quentin Eichbaum; Boris Julg; Jonathan L Jesneck; Kathleen Brosnahan; Sabrina Imam; Kate Russell; Ildiko Toth; Alicja Piechocka-Trocha; Douglas Dolfi; Jill Angelosanto; Alison Crawford; Haina Shin; Douglas S Kwon; Jennifer Zupkosky; Loise Francisco; Gordon J Freeman; E John Wherry; Daniel E Kaufmann; Bruce D Walker; Benjamin Ebert; W Nicholas Haining Journal: Nat Med Date: 2010-10-03 Impact factor: 53.440
Authors: Jacques Fellay; Kevin V Shianna; Dongliang Ge; Sara Colombo; Bruno Ledergerber; Mike Weale; Kunlin Zhang; Curtis Gumbs; Antonella Castagna; Andrea Cossarizza; Alessandro Cozzi-Lepri; Andrea De Luca; Philippa Easterbrook; Patrick Francioli; Simon Mallal; Javier Martinez-Picado; José M Miro; Niels Obel; Jason P Smith; Josiane Wyniger; Patrick Descombes; Stylianos E Antonarakis; Norman L Letvin; Andrew J McMichael; Barton F Haynes; Amalio Telenti; David B Goldstein Journal: Science Date: 2007-07-19 Impact factor: 47.728
Authors: Jens L Hukelmann; Karen E Anderson; Linda V Sinclair; Katarzyna M Grzes; Alejandro Brenes Murillo; Phillip T Hawkins; Len R Stephens; Angus I Lamond; Doreen A Cantrell Journal: Nat Immunol Date: 2015-11-09 Impact factor: 25.606
Authors: Deepti Gurdasani; Louise Iles; David G Dillon; Elizabeth H Young; Ashley D Olson; Vivek Naranbhai; Sarah Fidler; Effrossyni Gkrania-Klotsas; Frank A Post; Paul Kellam; Kholoud Porter; Manjinder S Sandhu Journal: AIDS Date: 2014-01-14 Impact factor: 4.177
Authors: Enrique Martin-Gayo; Ce Gao; Hsiao Rong Chen; Zhengyu Ouyang; Dhohyung Kim; Kellie E Kolb; Alex K Shalek; Bruce D Walker; Mathias Lichterfeld; Xu G Yu Journal: Cell Rep Date: 2020-01-28 Impact factor: 9.995
Authors: Julia Makinde; Eunice W Nduati; Anna Freni-Sterrantino; Claire Streatfield; Catherine Kibirige; Jama Dalel; S Lucas Black; Peter Hayes; Gladys Macharia; Jonathan Hare; Edward McGowan; Brian Abel; Deborah King; Sarah Joseph; Eric Hunter; Eduard J Sanders; Matt Price; Jill Gilmour Journal: Front Immunol Date: 2021-03-11 Impact factor: 7.561